Renal cell carcinoma (kidney cancer) is among the 10 most common cancers in both men and women, with 15-25 percent of patients having metastatic renal cell carcinoma (mRCC) where the cancer has spread to other parts of the body.
Typically, renal cell carcinoma is a disease that affects older individuals; average age at diagnosis is 64. In 2019, it is estimated the U.S. will see about 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women), and that nearly 14,700 individuals will die from this disease.
Source: American Cancer Society. Key Statistics about Kidney Cancer.
This CME, CNE, and CPE-accredited educational program is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapies into the treatment of renal cell carcinoma (RCC). The program will be presented in two formats: a live, on-site learning workshop and an audio-guided online course.
ACCC's Improving Quality Care in Renal Cell Carcinoma project seeks to improve the quality of care for renal cell carcinoma patients treated at community cancer programs.
Immunotherapy for Kidney Cancer: The Past, Present, and Future